Technical Analysis for C4XD - C4X Discovery Holdings plc

Grade Last Price % Change Price Change
B 43.25 0.55% 0.24
C4XD closed up 0.55 percent on Wednesday, December 1, 2021, on 2 percent of normal volume.
Earnings due: Dec 8
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
Historical C4XD trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.55%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.55%
Wide Bands Range Expansion 0.55%
MACD Bearish Signal Line Cross Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Older End-of-Day Signals for C4XD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 23 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 23 hours ago
1,2,3, Pullback Entry about 23 hours ago
Rose Above Previous Day's High about 23 hours ago
Fell Below Previous Day's Low 8 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


C4X Discovery Holdings plc Description

C4X Discovery Holdings plc is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics. Its products include Orexin-1, NRF-2, GPR142, GLP-1, Anti-IL-17, SGC Collaboration and Target 1. Its primary indication for its oral Orexin-1 antagonists is for the treatment of nicotine addiction as an aid to smoking cessation. It has two drug discovery programs targeting inflammatory disorders: oral Nrf-2 activators for the treatment of Chronic Obstructive Pulmonary disease (COPD) and oral/topical IL-17 inhibitors for the treatment of Psoriasis. IL-17 is implicated in multiple inflammatory and autoimmune diseases. Its suite of technologies include Taxonomy3, Conformetrix and MolPlex.


Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Biology Biopharmaceutical Health Sciences Drug Discovery Autoimmune Diseases Chronic Obstructive Pulmonary Disease Diabetes Inflammatory Disorders Psoriasis

Is C4XD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 54.5
52 Week Low 18.0
Average Volume 709,662
200-Day Moving Average 36.20
50-Day Moving Average 34.35
20-Day Moving Average 41.83
10-Day Moving Average 43.88
Average True Range 1.48
ADX 51.99
+DI 32.02
-DI 17.68
Chandelier Exit (Long, 3 ATRs) 40.96
Chandelier Exit (Short, 3 ATRs) 32.94
Upper Bollinger Bands 49.29
Lower Bollinger Band 34.36
Percent B (%b) 0.6
BandWidth 35.69
MACD Line 2.91
MACD Signal Line 3.27
MACD Histogram -0.3634
Fundamentals Value
Market Cap 97.89 Million
Num Shares 226 Million
EPS -5.00
Price-to-Earnings (P/E) Ratio -8.65
Price-to-Sales 0.00
Price-to-Book 4.30
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.45
Resistance 3 (R3) 44.33 43.82 44.25
Resistance 2 (R2) 43.82 43.51 43.88 44.18
Resistance 1 (R1) 43.53 43.32 43.65 43.65 44.12
Pivot Point 43.02 43.02 43.08 43.08 43.02
Support 1 (S1) 42.73 42.71 42.85 42.85 42.38
Support 2 (S2) 42.22 42.52 42.28 42.32
Support 3 (S3) 41.93 42.22 42.25
Support 4 (S4) 42.05